BCAL Diagnostics Ltd (ASX: BDX) Share Price and News

Mr Darling is a leader and executive who brings commercial experience from his prior role as CEO of Pacific Edge, a NZX50 and ASX listed business focused on commercialising its bladder cancer diagnostics tests across global markets, with commercial operations in New Zealand, Australia, Singapore and the USA. Prior to Pacific Edge, Mr Darling held management positions with Fletcher Challenge. Mr Darling has a background as a scientist with a specialty in genetics and has experience in developing and commercialising life sciences and biotechnology products. Mr Darling has dedicated his career to building and growing companies across the life sciences and biotechnology sectors where he focused on the growth and international commercialisation of these start-up and young companies. Mr Darling also brings governance and executive management experience having served as a director of Pacific Edge and its subsidiary businesses in New Zealand, Australia, Singapore and the USA. He is also a board director on a number of private business and organisation boards.

Ms Shaw was trained as a Registered Nurse in the UK, on arrival in Australia Jayne became a Director of Nursing and Chief Executive Officer of two private hospitals. Following this, Ms Shaw established an Australian and international consulting business which was sold to Healthsouth a US Healthcare company. Ms Shaw then became the Co-founder of Vision Group, an Opthalmic Doctor equity consolidation model that was listed on the ASX. Ms Shaw has been a member of a number of private healthcare boards involved with consolidation including cardiology, orthopaedics, and women's health, and continued to work with private equity firms on local and International Healthcare transactions. Ms Shaw, together with Mr Ronald Phillips, was a co-owner of Sydney Breast Clinic and a co-founder of BCAL Diagnostics.

Dr Hurrell has developed and commercialized multiple products and services in life sciences and diagnostics over a career in the industry spanning more than 35 years. He has developed and managed start-up and early-stage companies including life science companies based on university-developed technologies. Dr Hurrell spent almost 7 years in managerial and executive roles with NYSE-listed, Fortune 500 clinical laboratory company Quest Diagnostics. Within Quest's subsidiary Focus Diagnostics, he led the development and launch of more than 70 molecular diagnostics tests and gained 510(k) approvals for 6 products. He also served as VP of Business Development at Quest Diagnostics. Other previous roles include Senior Vice President, US R&D Operations for Boehringer Mannheim, now Roche Diagnostics, a remote chronic disease patient management company with a focus on diabetes and kidney disease, President of the Asia/Pacific region and Head of International Sales for PTS Diagnostics, a diabetes and wellness company based in Indiana, USA, and Senior Executive Vice President International Business for Seegene Inc., a multinational molecular diagnostics company focusing on infectious disease, based in Seoul, South Korea.

Mr Trollip is a globally experienced professional non-executive Director with over 30 years of commercial, corporate, governance and legal and transactional expertise. He has interest in the not-for-profit sector, is chairman of the PNI Foundation and is involved at board level and a contributor with other not for profit organisations in Australia and Southern Africa in the education sector and in wildlife conservation. Mr Trollip is the Chair of the Risk Management Committee.

-

-

-

-

-